Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on February 15, 2008, reporting significant changes in its corporate governance structure. The key event is the retirement of James D. Robinson III as Chairman of the Board, effective February 11, 2008. Concurrently, James M. Cornelius, who already held the position of Chief Executive Officer, was elected as the new Chairman of the Board, consolidating these two leadership roles. These changes were formalized through amendments to the company's bylaws, which now combine the roles of Chairman and CEO and also incorporate the position of a Lead Independent Director, with Lewis B. Campbell appointed to this role. The report also details the termination of Mr. Cornelius's previous employment agreement, with his compensation to be determined as part of the annual senior management review. Investors should note this consolidation of power and the establishment of a Lead Independent Director as potential indicators of strategic shifts or governance adjustments within the company.
Key Highlights
- 1James D. Robinson III retired as Chairman of the Board on February 11, 2008.
- 2James M. Cornelius, CEO, was elected Chairman of the Board, combining the CEO and Chairman roles.
- 3Lewis B. Campbell was appointed Lead Independent Director.
- 4The company amended its bylaws to combine the Chairman and CEO positions and to reference the Lead Independent Director.
- 5The prior employment agreement for Mr. Cornelius was terminated effective February 12, 2008.
- 6Mr. Cornelius will continue to receive his current base salary of $1,400,000 until his new compensation is determined.
- 7Mr. Robinson will remain a director until the 2008 Annual Meeting of Stockholders.